Back to the Future: Improving Use of Guidelines-Recommended Coronary Disease Secondary Prevention at the Dawn of the Precision Medicine Era
This is an interesting and exciting time in medicine. The confluence of high throughput molecular assay platforms, sophisticated informatics capabilities, and cloud computing have us poised for the advent of an era of medical therapy in which it will be possible to more precisely define which patients are most likely to benefit from treatment with a given drug or have the best benefit to risk profile and tailor therapy accordingly. Yet, even as we revel in the promise and future possibilities of precision medicine in cardiovascular disease, it is important not to lose our focus on what we can and should do for our coronary artery disease (CAD) patients today. Although it is true that the current process of developing and testing new therapies and resultant treatment recommendations has followed a "one-size-fits-all" approach, we have learned much about adherence to evidence-based medicine and performance improvement and their relationships to improved clinical outcomes at the population level.
- Received February 17, 2015.
- Accepted February 19, 2015.